News | July 23, 2021
Biocon Q1FY22 revenue up 6% at Rs 1,808 Cr
Q1 FY22 consolidated revenue grew 6% to Rs. 1,808 crore from Rs. 1,712 crore in Q1 FY21. Q1 FY22 Net Profit was Rs. 84 crore (vs. Rs. 149 crore in Q1 FY21).
Q1 FY22 consolidated revenue grew 6% to Rs. 1,808 crore from Rs. 1,712 crore in Q1 FY21. Q1 FY22 Net Profit was Rs. 84 crore (vs. Rs. 149 crore in Q1 FY21).
The company has reported PAT of Rs. 10.7 crore for Q1 FY22, higher by 23% YoY
Drop in revenue in the fourth quarter is normal as China is shut down for most of the quarter due to the Chinese New Year holiday
The progress has been encouraging with approvals and launches in the US, EU, Japan, Australia and Emerging Markets. Post Mylan Upjohn (Pfizer) merger, the scope has been extended to China as well.
Both the vaccines have been extensively tested by IVRI for safety and potency and have been found to provide 100% protection
Vivimed strategy is to increase its share of Branded products in CIS Markets.
Subscribe To Our Newsletter & Stay Updated
